You are here
Business Development and Partnering
From academia to industry and advocates to companies, Pfizer seeks collaborations that will advance discoveries and the development of new therapies for patients with rare diseases. Together, we can gain knowledge faster, whether in discovery, clinical, or commercial stages, to speed the delivery of new medicines to patients most in need.
Pfizer Rare Disease Business and Partnering Focuses on a Broad Range of Therapeutic Areas and Novel Platforms Including
- Inherited Metabolic/Endocrine
- Gene Therapy
Partnering on Discovery Through Early-Stage Clinical Development
For partnering at the earlier stages of development (generally prior to clinical proof-of-concept) in Rare Disease, please contact the Pfizer External Research & Development Innovation (ERDI) group within Worldwide Research & Development (WRD).
Partnering on Late-Stage Clinical Development Through Commercialization
For partnering on late-stage opportunities (generally after clinical proof-of-concept) in Rare Disease, please contact the Pfizer Worldwide Business Development group within Biopharmaceuticals – Global Innovative Pharma (GIP).